

In the Claims:

Listing of the Claims:

Please amend claims 1 and 26 as indicated. Please add claims 32 and 33 as indicated.

1. (Twice Amended) A vaccine useful for the treatment of melanoma comprising irradiated autologous melanoma cells conjugated to a hapten, said hapten selected from the group consisting of [trynitrophenyl] trinitrophenyl and N-iodoacetyl-N'-5 sulfonic 1-naphtyl ethylene diamine; and mixed with an immunological adjuvant, wherein said immunological adjuvant is Bacille Calmette-Guerin.
2. (Previously Presented) A method for treating melanoma comprising administering cyclophosphamide followed by intradermal administration of a therapeutically effective amount of the vaccine of claim 1, wherein said vaccine induces a delayed-type hypersensitivity (DTH) response against unmodified melanoma cells.
3. Canceled
4. Canceled
5. Canceled
6. Canceled
7. Canceled
8. Canceled
9. Canceled
10. Canceled
11. Canceled
12. Canceled
13. Canceled
14. Canceled
15. Canceled
16. Canceled
17. Canceled
18. Canceled
19. Canceled
20. Canceled

21. (Previously Presented) The vaccine of claim 1, wherein said autologous melanoma cells are cryopreserved.
22. (Previously Presented) The method of claim 2, wherein said autologous melanoma cells are cryopreserved.
23. (Previously Presented) The method of claim 2, wherein said vaccine is injected into three contiguous sites on an upper arm or leg.
24. (Previously Presented) The method of claim 2, wherein said vaccine is administered to post-surgical melanoma patients.
25. (Previously Presented) The method of claim 2, wherein said vaccine is administered to stage four melanoma patients.
26. (Amended) A method for treating melanoma comprising administering cyclophosphamide followed by intradermal administration of a therapeutically effective amount of a vaccine composition comprising autologous irradiated melanoma cells conjugated to a hapten, said hapten selected from the group consisting of dinitrophenyl, [trinitrophenyl] trinitrophenyl, and N-iodoacetyl-N'-5 sulfonic 1-naphtyl ethylene diamine and mixed with Bacille Calmette-Guerin, wherein administration of said vaccine induces a delayed-type hypersensitivity (DTH) response against unmodified melanoma cells.
27. (Previously Presented) The method of claim 26, wherein said vaccine is injected into three contiguous sites on an upper arm or leg.
28. (Previously Presented) The method of claim 26, wherein said vaccine is administered to post-surgical melanoma patients.
29. (Previously Presented) The method of claim 26, wherein said vaccine is administered to stage four melanoma patients.
30. (Previously Presented) The method of claim 26, wherein said vaccine is administered every four weeks.
31. (Previously Presented) The method of claim 26, wherein said autologous melanoma cells are cryopreserved.
32. (New) The vaccine of claim 1, further comprising an immunomodulating drug.
33. (New) The vaccine of claim 32, wherein the immunomodulating drug is IL-2.